BC Week In Review | Jun 1, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease (COPD) after the drug missed the primary endpoint of reducing exacerbations in a...
BC Extra | May 30, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease after the drug missed the primary endpoint of reducing exacerbations in a second...
BC Week In Review | May 18, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from...
BC Extra | May 11, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from...
BC Innovations | Nov 19, 2015
Product R&D

A solid move

Following its IPO in March, Cantargia AB is shifting the focus of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb affects the tumor microenvironment as well as...
BC Week In Review | Sep 15, 2014
Clinical News

Benralizumab: Phase IIa data

Data from 82 patients with moderate to severe COPD and an elevated sputum eosinophil count in the per protocol (PP) population of a double-blind, international Phase IIa trial in 101 patients showed that subcutaneous benralizumab...
BC Week In Review | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

AstraZeneca disclosed in its 2Q14 earnings that it began the double-blind, double-dummy, placebo-controlled, international Phase III Terranova trial to evaluate 3 doses of subcutaneous benralizumab in about 4,850 COPD patients with moderate to very severe...
BC Week In Review | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

AstraZeneca disclosed in its 2Q14 earnings that it began the double-blind, double-dummy, placebo-controlled, international Phase III Galathea trial to evaluate 2 doses of subcutaneous benralizumab in about 3,788 COPD patients with moderate to very severe...
BC Week In Review | Jun 30, 2014
Clinical News

Benralizumab: Phase IIb data

A double-blind, international Phase IIb trial in 606 patients with uncontrolled asthma and elevated baseline blood eosinophil levels showed that 100 mg subcutaneous benralizumab met the primary endpoint of reducing annual exacerbation rate at week...
BC Week In Review | Mar 24, 2014
Company News

arGEN-X B.V., Lonza, Kyowa Hakko Kirin deal

arGEN-X received non-exclusive rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell line technology to arGEN-X's ARGX-110 . The human mAb against CD70 (CD27L) is in Phase Ib testing for CD70-positive...
Items per page:
1 - 10 of 54
BC Week In Review | Jun 1, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease (COPD) after the drug missed the primary endpoint of reducing exacerbations in a...
BC Extra | May 30, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease after the drug missed the primary endpoint of reducing exacerbations in a second...
BC Week In Review | May 18, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from...
BC Extra | May 11, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from...
BC Innovations | Nov 19, 2015
Product R&D

A solid move

Following its IPO in March, Cantargia AB is shifting the focus of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb affects the tumor microenvironment as well as...
BC Week In Review | Sep 15, 2014
Clinical News

Benralizumab: Phase IIa data

Data from 82 patients with moderate to severe COPD and an elevated sputum eosinophil count in the per protocol (PP) population of a double-blind, international Phase IIa trial in 101 patients showed that subcutaneous benralizumab...
BC Week In Review | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

AstraZeneca disclosed in its 2Q14 earnings that it began the double-blind, double-dummy, placebo-controlled, international Phase III Terranova trial to evaluate 3 doses of subcutaneous benralizumab in about 4,850 COPD patients with moderate to very severe...
BC Week In Review | Aug 18, 2014
Clinical News

Benralizumab: Phase III started

AstraZeneca disclosed in its 2Q14 earnings that it began the double-blind, double-dummy, placebo-controlled, international Phase III Galathea trial to evaluate 2 doses of subcutaneous benralizumab in about 3,788 COPD patients with moderate to very severe...
BC Week In Review | Jun 30, 2014
Clinical News

Benralizumab: Phase IIb data

A double-blind, international Phase IIb trial in 606 patients with uncontrolled asthma and elevated baseline blood eosinophil levels showed that 100 mg subcutaneous benralizumab met the primary endpoint of reducing annual exacerbation rate at week...
BC Week In Review | Mar 24, 2014
Company News

arGEN-X B.V., Lonza, Kyowa Hakko Kirin deal

arGEN-X received non-exclusive rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell line technology to arGEN-X's ARGX-110 . The human mAb against CD70 (CD27L) is in Phase Ib testing for CD70-positive...
Items per page:
1 - 10 of 54